This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
42
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Glendale, California, United States
Number of Participants With Clinically Significant Effects
Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module. The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.
Time frame: Predose up to Day 70
Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721
Time frame: Predose (Day 14) up to Day 19
Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721
Area under the concentration versus time curve during 1 dosing interval (1 dosing interval=24 hours) at steady state (AUCτ,ss) is being reported for this outcome measure.
Time frame: Predose (Day 14) to 24 Hours post-dose (Day 15)
Plasma Amyloid Beta (Aβ) 1-40 Concentration
The minimum concentration (Cnadir) is being reported for this outcome measure.
Time frame: Predose (Day 14) up to Day 19
Cerebrospinal Fluid (CSF) Concentration of LY2886721
Time frame: 24 Hours post-dose (Day 15)
Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration
The Least Squares means were adjusted for baseline concentration.
Time frame: Predose (Day 14), 24 Hours post-dose (Day 15)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.